KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Current Leases (2019 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Current Leases for 7 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 13.04% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, up 13.04% year-over-year, with the annual reading at $2.8 million for FY2025, 13.04% up from the prior year.
  • Current Leases hit $2.8 million in Q4 2025 for Inovio Pharmaceuticals, up from $2.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.8 million in Q4 2025 to a low of $2.1 million in Q3 2023.
  • Historically, Current Leases has averaged $2.5 million across 5 years, with a median of $2.6 million in 2021.
  • Biggest five-year swings in Current Leases: dropped 24.92% in 2023 and later increased 19.48% in 2025.
  • Year by year, Current Leases stood at $2.6 million in 2021, then grew by 7.68% to $2.8 million in 2022, then decreased by 14.17% to $2.4 million in 2023, then rose by 3.77% to $2.5 million in 2024, then increased by 13.04% to $2.8 million in 2025.
  • Business Quant data shows Current Leases for INO at $2.8 million in Q4 2025, $2.7 million in Q3 2025, and $2.7 million in Q2 2025.